Overall rank by patents
#25,050
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 3 technology areas, active 2019–2023. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR).
The verdict
Repro-med holds 11 US patents across 3 technology areas, rank #25,050 of 50,000 tracked assignees.
Repro-med Systems, Inc. has been granted 11 US utility patents between 2019 and 2023, placing Repro-med Systems, Inc. at rank #25,050 across all assignees tracked by PlainPatent. This portfolio spans 3 distinct Cooperative Patent Classification (CPC) subclasses, averaging 33.6 claims per patent with primary concentration in A61M (DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY ; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY ; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR). As a US Corporation, Repro-med Systems, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Repro-med sits between Realta Holdings, Llc (11 patents, rank #25,046) and Rhapsody International Inc. (11 patents, rank #25,054) - the closest US assignees by grant volume. The composite Innovation Score of 32.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 7 grants, compared with 4 in the 2015–2019 window, a +75% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Repro-med Systems, Inc.'s 33.6 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while specialization in 3 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Repro-med Systems, Inc. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
REALTA HOLDINGS, LLC
11 patents
REM Technology Inc.
11 patents
REMACRO TECHNOLOGY CO., LTD.
11 patents
REMD Biotherapeutics, Inc.
11 patents
REPUBLIC BRANDS L.P.
11 patents
RETRAX HOLDINGS, LLC
11 patents
RF ELEMENTS SRO
11 patents
RHAPSODY INTERNATIONAL INC.
11 patents
REPRO-MED SYSTEMS, INC.
11 patents
What this shows Repro-med holds 11 patents at rank #25,050, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Repro-med's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 60% higher than 40% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 4 | 36.4% |
| 2020 | 3 | 27.3% |
| 2021 | 1 | 9.1% |
| 2022 | 2 | 18.2% |
| 2023 | 1 | 9.1% |
Top 3 of 3 technology areas
Overall rank by patents
#25,050
Across all tracked assignees
32.2 out of 100
How to use this portfolio
Repro-med's 11 grants land it in the top 60% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.